Pneumonia Vaccine Market News Research Report 2030

Pneumonia can be defined as lung infection which affects the air sacs and fills them up with fluid or pus. Infants below the age of two years and adults over the age of 65 years are at the higher risk of acquiring pneumonia.

Pneumococcal diseases are considered to be common among children and adults. Elderly population is significantly prone to these infections, which might even lead to death. Pneumonia vaccines are usually administered to children less than two years of age and to adults over 65 years of age.
Pneumonia vaccine aids in fighting and provides immunization against over 13 types of pneumococcal bacteria known to cause infection in the lungs

The global annual incidence of pneumonia is considered to be over 150.7 million cases according to the WHO Child Health Epidemiology Reference Group. In addition, over 95% of all these cases are known to be occurring in the developing countries. Furthermore, over 150 million new cases of pneumonia are known to occur in children below five years of age, leading to nearly 20 million hospitalizations annually at a global level. This high prevalence of pneumonia in children globally contributes to the growth of the pneumonia vaccines market.
Growing geriatric population along with the increasing prevalence of pneumococcal infections, makes the aging population more prone to infections, contributing to the rise in demand for pneumonia vaccines.

Furthermore, people with weakened immune system, including people suffering from heart disease, diabetes, smokers, and heavy drinkers, are more likely to get pneumonia. Increase in the population with weakened immune system contributes to the demand for pneumonia vaccine aiding in the growth of the market.

In terms of region, the global pneumonia vaccine market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
North America dominated the global pneumonia vaccine market in 2018, owing to strong presence of leading market players, high prevalence of pneumonia, increasing government focus on immunization programs, and advancements in administration of vaccines
Europe was the second largest market for pneumonia vaccine in 2018, followed by Asia Pacific. Asia Pacific is projected to be the fastest growing market for pneumonia vaccine, followed by Latin America and Middle East & Africa. Growing focus of the governments in countries in Asia on enhancing healthcare facilities, government initiatives, rising disposable income, and rapid economic development contribute to the growth of the pneumonia vaccine market in the region.

Glaxosmithkline plc.
LG Chem Ltd.
Merck & Co., Inc.
Panacea Biotec Limited
Pfizer Inc.
Pnuvax Incorporated
Serum Institute of India Pvt. Ltd.
Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
SK Bioscience
Walvax Biotechnology Co., Ltd.

Read our Case study at : https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

North America
- U.S.
- Canada
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa